99%+ Purity
COA Included
Sealed Vials
Retatrutide
Triple agonist (GLP-1/GIP/Glucagon) for aggressive fat loss
Triple agonist fat-loss hammer
Key Benefits
- Triple-pathway metabolic system activation
- May support significant body composition changes
- Enhanced appetite and satiety regulation
- Potential improvements in glucose metabolism
- Increased energy expenditure and fat utilization
- Convenient once-weekly dosing protocol
- Superior results versus single-target approaches
The Fat Loss Compound That Hits All Three Pathways
Most fat loss compounds target one pathway and leave metabolic gaps that sabotage results. Retatrutide activates three critical systems simultaneously—appetite control, insulin optimization, and direct fat burning—creating the kind of aggressive, sustainable fat loss that single-target approaches simply can't deliver. This is what happens when you stop fighting your metabolism and start orchestrating it.
Triple hormone receptor activation (GLP-1/GIP/Glucagon pathways for comprehensive metabolic control)
About Retatrutide
Retatrutide is the first triple-receptor agonist designed specifically for aggressive fat loss without metabolic compromise. By simultaneously activating GLP-1, GIP, and glucagon receptors, it creates a coordinated metabolic response that controls appetite, optimizes glucose handling, and directly increases fat oxidation. The result is sustained fat mobilization with improved energy levels rather than the typical crash associated with aggressive cutting phases.
Who It's For
Ideal for individuals who have hit plateaus with traditional approaches or need significant body composition changes without sacrificing metabolic health. The once-weekly protocol makes it highly practical for long-term use, while the triple-pathway approach addresses the multiple metabolic bottlenecks that typically limit fat loss progress. This represents a fundamental shift from single-target interventions to comprehensive metabolic orchestration.
Research Background
Retatrutide represents a breakthrough in metabolic therapeutics as the first triple-hormone receptor agonist designed for weight management. Unlike traditional weight loss medications that target single pathways, retatrutide simultaneously activates three crucial metabolic systems: GLP-1 receptors (controlling appetite and blood sugar), GIP receptors (enhancing insulin sensitivity), and glucagon receptors (boosting energy expenditure and fat burning). This comprehensive approach addresses multiple aspects of energy balance, creating synergistic effects that surpass single-target therapies. Research focuses on optimizing this triple mechanism to maximize fat loss while minimizing side effects, particularly gastrointestinal symptoms common with incretin-based therapies. Current investigations examine: 1) Optimal dosing strategies to balance efficacy with tolerability, 2) Long-term safety profiles in diverse patient populations, and 3) Combination approaches with lifestyle interventions. The compound's remarkable clinical trial results, showing up to 24% weight loss, have positioned it as a potential game-changer in obesity treatment, addressing the urgent need for more effective pharmaceutical interventions in the global obesity epidemic.
Dosing Protocol
| Level | Dose | |
|---|---|---|
Beginner | 0.25 mg/wk | |
Intermediate | 0.5-1 mg/wk | |
Advanced | 2-4 mg/wk | |
Maximum | 4-8 mg/wk |
Select a dosing level and click Calculate to plan your protocol.
Vials Required
1
9.0 mg needed ÷ 10 per vial
Total Investment
$100
$100.00 per vial
Per Dose
0.07 mL
8 units on U-100 syringe
Doses per Vial
13
10 ÷ 0.75 mg/dose
* Calculations based on standard reconstitution protocols. Consult research guidelines for specific applications.
Compliance & Disclaimer
This product is intended for laboratory research purposes only. Not for human consumption. All products are sold with the understanding that the purchaser will comply with all applicable local, state, and federal laws regarding the purchase and use of research chemicals. Certificate of Analysis available upon request.
Retatrutide
$100.00